Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy

NCT07704099 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: KER-065

Sponsor

Keros Therapeutics, Inc.